Natural History Study for Eye Cancer

Not currently recruiting at 17 trial locations
RN
Overseen ByResearch Nurse Navigator
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Columbia University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on understanding uveal melanoma, a type of eye cancer, by creating a registry to track the disease's progression over time. The goal is to gather data to aid in developing new treatments. Individuals diagnosed with uveal melanoma who can consent to participate are suitable for this study. By collecting and analyzing this information, researchers aim to improve care and treatment options for this condition.

As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to better future treatments.

Why are researchers excited about this trial?

Unlike the standard treatments for uveal melanoma, which typically involve surgery, radiation, or laser therapy, this trial is exploring the natural history of the condition. Researchers are excited about this approach because it aims to better understand how uveal melanoma progresses without intervention. By observing the course of the disease, scientists hope to identify key factors influencing its development and potentially discover novel targets for future therapies. This could pave the way for more effective and personalized treatment strategies in the future.

Who Is on the Research Team?

ME

Mariam El-Ashmawy, MD, PhD

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

Inclusion Criteria

Diagnosis of uveal melanoma
Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Management

Initial management of primary uveal melanoma directed by an ophthalmologic oncologist

Varies

Surveillance

Surveillance for the development of metastasis following treatment of primary disease

Up to Five years

Treatment of Recurrent Disease

Management of recurrent or metastatic disease directed by a medical oncologist

Varies

Follow-up

Participants are monitored for overall survival and relapse-free survival

Up to Five years

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Columbia University

Lead Sponsor

Trials
1,529
Recruited
2,832,000+

Richard D. Carvajal

Lead Sponsor

Trials
4
Recruited
770+